The Coming Successor and the Ending Humira
On January 31, Amgen announced that its Humira (Adalimumab) biosimilar, Amjevita (adalimumab-atto), had entered into the American market officially.And Amjevita is also the first adalimumab biosimilar approved by FDA.
March 1, 2023
by Yi/PharmaSources
Alpine Immune, Horizon enter autoimmune disease research collaboration
Alpine Immune Sciences and Horizon Therapeutics have signed an exclusive licence and collaboration agreement to develop protein-based therapies to treat autoimmune and inflammatory diseases.
December 21, 2021
by Pharmaceutical-Business-Review
Merck signs agreement to buy Pandion Therapeutics for $1.85bn
Merck has agreed to acquire biotechnology company Pandion Therapeutics for approximately $1.85bn to expand its portfolio of autoimmune disease-targeting candidates.
March 1, 2021
by pharmaceutical-technology
Lenabasum Study for Systemic Sclerosis Does Not Meet Primary Endpoint
Corbus Pharmaceuticals has announced topline results from the 52-week Phase 3 RESOLVE-1 study of lenabasum in patients with diffuse cutaneous systemic sclerosis (SSc). SSc is a rare and life-threatening multi-system autoimmune disease for which there ...
September 23, 2020
by americanpharmaceuticalreview
Eisai Enters Joint Research Alliance to Create SLE Treatment
Aims to create a Japan-originated therapeutic drug for systemic lupus erythematosus using Eisai’s new oral Toll-Like Receptor 7/8 inhibitor E6742.
July 14, 2020
by contractpharma
Exagen Partners with Sonora Quest to Offer AVISE Testing for Autoimmune Disease
Exagen has entered into a strategic partnership with Sonora Quest. The agreement provides preferred access through Sonora Quest in Arizona to Exagen’s AVISE testing.
March 17, 2020
by americanpharmaceuticalreview
SciRhom Initiates First-In-Class Antibody Development Program to Treat Major Autoimmune Diseases
SciRhom GmbH, a therapeutic antibody company, announced the development of first-in-class antibodies against iRhom2, a key modulator of several major pro-inflammatory signaling pathways ...
November 6, 2019
by b3cnewswire
Bio-macromolecular Drugs in the Autoimmune Disease Field in China
Focus on the bio-macromolecular drugs in the autoimmune disease field that have been marketed or in the marketing review stage in China, overall, including 9 marketed drugs and 6 drugs in the marketing review.
February 13, 2019
by PharmaSources/1℃
US grants AZ’ Fasenra orphan drug status for rare autoimmune disease
US regulators have granted AstraZeneca’s Fasenra Orphan Drug Designation (ODD) for the treatment of Eosinophilic Granulomatosis with Polyangiitis (EGPA), a rare and potentially fatal autoimmune disease.
November 27, 2018
by pharmatimes
Alvotech teams with Fuji Pharma for biosimilar portfolio in Japan
Alvotech’s products are used in advanced therapies such as oncology, and autoimmune disease. Credit: Alvotech.
November 21, 2018
by pharmaceutical
Johnson & Johnson drops OSE’s rheumatoid arthritis drug
Johnson & Johnson has dumped OSE Immunotherapeutics’ autoimmune candidate FR104. J&J picked up the rights to the CD28 antagonist for...
November 5, 2018
by fiercebiotech
New Research Suggests Glaucoma May Be an Autoimmune Disease
The eye disease glaucoma may be an autoimmune disorder, a new study suggests.
August 13, 2018
by drugs